Why We Think Louisiana-Pacific (NYSE: LPX) Stock is a Buy

2215 0 0 0 0 0 (0)

As housing demand has been steadily falling for the last 5 months and interest rates steadily rising one might come to the conclusion that Louisiana-Pacific Corp (NYSE: LPX) stock is not a buy right now. We have a different outlook on LPX stock, and that is what we do, find the few stocks that are going unnoticed and potentially have plenty of nice upsides. At Hade Platform we like to think of it as the holy grail of investing, finding the biggest winning stocks in the market. The outliers. The stocks that break all of the records ... i.e., the leaders. The Paper & Forest Products industry is estimated to be a $94 billion enterprise. LPX income growth has significantly exceeded that of the S&P 500 and the Paper & Forest Products industry. We feel that this trend should continue despite the depreciating US dollar, increasing energy and transportation costs, and rising raw material costs. We believe the strengths outweigh the risks and rate the company a buy. 

Register now for the world's best investment ideas

Over the past week, LPX stock investment grade on the Hade Platform has risen steadily, making it a Top 30 stock. Ironically, this stability in overall rating happens during a time when the overall market is falling, and as our investment grades as an average have consistently declined for the last four months, effectively predicting a correction which is exactly what happened. 

With overall investment grades still lower, we suggest holding large sums of cash and being very selective when making investment decisions. According to LPX stock’s current grade, it might very well be one of those selective opportunities. Why should you trust our ratings? The Hade Platform has proven over the course of three years through the application of DLAs and artificial intelligence that it consistently outperforms Wall Street consensus estimates (63%) and major benchmarks such as the S&P 500 (250%). Access our premium services and start beating the market.


Free users on Hade Platform can build a watchlist of stocks and access investment grades from our database of more than 4,000 securities. Premium members can access the platform to get an instant look at which stocks rate highest for value, growth, dividend, and which have the greatest short-term momentum, thereby allowing members to identify areas of opportunity. Premium services include interest trends, risk analysis, machine learning predictions, Top 100 stocks, MatriX Portfolio and more.


Comments (0)

Recent Updates

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Consumer Healthcare Total Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Consumer Helathcare Other of which Gold Bond Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Polio/Pertussis/Hib Vaccines (incl. Hexaxim/Hexyon, Pentacel, Pentaxim and Imovax) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Influenza Vaccines (incl. Vaxigrip, Fluzone HD, Fluzone, Flublok) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Meningitis/Pneumo Vaccines (incl. Menactra) Revenue

  •   
    Jan 19, 2019 9:38 AM

    Sanofi SA (ADR) - Vaccines Adult Booster Vaccines (incl. Adacel) Revenue